Background Multidrug-resistant (MDR) tuberculosis is a potential threat to tuberculosis elimination, but the extent of MDR tuberculosis disease in the USA that is attributable to transmission within the country is unknown. We assessed transmission of MDR tuberculosis and potential contributing factors in the USA.
Introduction
Drug-resistant tuberculosis is a major public health problem worldwide. [1] [2] [3] [4] [5] WHO estimates that more than 650 000 cases of multidrug-resistant (MDR) tuberculosis-defi ned as Mycobacterium tuberculosis resistant to at least isoniazid and rifampicin-emerge globally every year. 6 The development of drug resistance can be attributed to several factors, such as poor adherence to treatment, inadequate clinical management, drug malabsorption, and unstable drug supply. 7 Person-toperson transmission of MDR tuberculosis could be further fuelled by slow bacteriological conversion, delayed diagnosis and initiation of MDR-specifi c treatment, and treatment failure, as suggested by widespread outbreaks and secondary transmission of MDR tuberculosis within individual households and communities. [8] [9] [10] Migration of foreign-born individuals from areas with a high burden of MDR tuberculosis to those with a low burden could be an important factor. [11] [12] [13] A multiyear study of all cases of MDR tuberculosis reported in California, USA, showed that 92% were foreign-born individuals. 14 MDR tuberculosis has a substantial economic eff ect on programmatic activities, which is a result of treatment costs of long regimens, frequent admissions to hospital, and the necessary use of injectable drugs. 15 Although some control programmes have successfully reduced transmission of MDR tuberculosis, [16] [17] [18] the extent of MDR tuberculosis attributable to transmission in the USA is unknown. Previous studies 14, 17, 18 have not had wide geographical scopes or in-depth examination of epidemiological and clinical information that is necessary to confi rm transmission. In this study, we analysed M tuberculosis genotyping data and interpersonal connections between cases of MDR tuberculosis to assess potential factors contributing to transmission in eight US states.
Methods

Study population
This cross-sectional study was undertaken by the Tuberculosis Epidemiologic Studies Consortium (TBESC). 19 It in cluded all verifi ed cases of MDR tuberculosis reported to the US National Tuberculosis Surveillance System (NTSS) and National Tuberculosis Genotyping Dec 31, 2008 . Study periods were staggered because of delays in study approval in several sites and extended funding in California.
The institutional review boards of the Centers for Disease Control and Prevention (CDC) and all participating institutions 19 approved the study. All interviewed participants gave written informed consent.
Procedures
Clinical, demographic, epidemiological, and M tuberculosis genotype variables for each case were obtained during routine surveillance, as described elsewhere. 20 Additionally, for all individuals who gave consent, interviews (with a structured and standardised face-to-face questionnaire) and health-record abstraction were done by trained study staff to ascertain potential interpersonal connections (appendix). Health records were hospital-based medical records and public health records, which included contact investigation logs.
We defi ned drug resistance as any resistance on a drug susceptibility test (DST) reported to NTSS or identifi ed during health-record abstraction. Results from conventional DST (ie, liquid-based or agar-based media) were used for NTSS reporting. Results of rapid drugresistance tests (ie, molecular beacon, line probe assay, or other molecular test) were not included.
Isolates of the M tuberculosis complex were characterised with a standardised protocol for spacer oligonucleotide typing (spoligotyping), mycobacterial inter spersed repetitive-unit-variable-number tandem-repeat (MIRU-VNTR) genotyping, and IS6110 restriction fragment length polymorphism (IS6110-RFLP) analysis as part of routine molecular surveillance at two contract laboratories with documented quality of performance and reproducibility. 20, 21 For the purposes of this study, a genotype was defi ned as a discrete combination of spoligotype and 12-locus MIRU-VNTR results (ie, an exact match on all loci). When available, extended typing methods, 24-locus MIRU-VNTR, or IS6110-RFLP fi ngerprinting, or any combination of the three, were done to increase specifi city. 21 We defi ned genotype clusters as at least two cases of MDR tuberculosis, of which at least one was a study case, that had matching genotypes in a specifi c TBESC state between Jan 1, 2005, and June 30, 2011 (surveillance period). We created the surveillance period to allow suffi cient time to estimate recent transmission within genotype clusters and to include potential transmission events with non-study cases. When extended typing methods were available, we defi ned genotype clusters as at least two cases of MDR tuberculosis with matching genotype and extended method data (ie, exact match on all 24-loci MIRU-VNTR or IS6110-RFLP patterns). Study cases with no matching genotype, or, when applicable, with matching genotype but diff erent extended typing results, were deemed to be non-clustered. A conservative approach to defi nition of genotype clusters was taken, because nationally defi ned cluster proportions were shown to be greater than 75% in other studies. 22, 23 We defi ned epidemiological links as named contacts or shared transmission venues identifi ed during interview or documented as part of standardised tuberculosis contact investigation activities. 24 Briefl y, contact investigations are multistep processes, in which contacts are systematically assessed on the basis of the amount of time spent with the infectious person, the environmental conditions of the transmission venue, and the host susceptibility to tuberculosis infection in individuals who are in close contact. 24, 25 Although genotype cluster defi nitions were based on state, the same strain could be in several states, and we applied no restriction for documentation of transmission occurring between states or set by arbitrary periods through epidemiological links.
We defi ned an index case as the fi rst case of tuberculosis identifi ed in a genotype cluster by case date (eg, earliest count date, treatment start date, or report date). Spoligotype and 12-locus MIRU-VNTR results were used to assign phylogenetic lineage, as described elsewhere. 26 To establish the likelihood of transmission in the USA, we classifi ed cases on the basis of genotype, report date, and epidemiological link. Unlikely transmission was defi ned as cases of MDR tuberculosis with non-clustered genotypes reported in the same state (with or without extended typing data), and no epidemiological link. Possible transmission was defi ned as study cases for which at least one other case of MDR tuberculosis with matching genotype (with or without extended typing data) had been reported in the same state, but with no epidemiological link. Defi nite transmission was defi ned as study cases with at least one other case of MDR tuberculosis with matching genotype (with or without extended typing data) and an epidemiological link. To classify the reason for disease occurrence, we developed seven categories (table 1) .
Statistical analyses
We compared the distribution of clinical, demographic, and epidemiological characteristics of clustered and nonclustered cases of MDR tuberculosis with diff erences of proportion, as assessed by Pearson's χ² or Fisher's exact test when the cell count was less than fi ve. We used the Shapiro-Wilk test to test for normality. Unless otherwise specifi ed, we used median values with IQRs as a measure of central tendency to avoid extreme values. We used relative risk and 95% CIs to assess the association of specifi c variables with the outcome of tuberculosis transmission. We used SAS (version 9.3) for all analyses.
Role of the funding source
The CDC Division of Tuberculosis Elimination and the TBESC led study design, training for data collection and monitoring, data analysis, data interpretation, and writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
During the study periods, 29 050 verifi ed cases of tuberculosis were reported in the USA. Of these, 22 725 (78%) were culture positive, including 22 222 (76%) with DST results for isoniazid and rifampicin. Of individuals with reported DST results, 268 (1%) had MDR tuberculosis. 168 (63%) of these individuals with MDR disease were reported from the eight study sites, of whom 92 (55%) consented to an in-depth interview. For the other 76 (45%), analysis was limited to routinely obtained surveillance variables. Individuals who were members of genotype clusters were more likely to be male (p<0·0001), be Hispanic (p<0·0001), be in prison at time of diagnosis (p=0·01), and have an M tuberculosis isolate of Euro-American lineage (p=0·004) than were non-members (table 2) . 144 individuals (86%) with MDR tuberculosis were born outside of the USA, but the proportion of individuals born outside the USA who were or were not members of clusters did not diff er signifi cantly (p=0·53; table 2). Additionally, we recorded no signifi cant diff erences in clinical characteristics-the proportion with a positive sputum smear (p=0·77), pulmonary disease (p=0·37), or cavitation on chest radiography (p=0·35) did not signifi cantly diff er between cases that were and were not part of a genotype cluster (table 2) .
Clinical, demographic, and genotypic characteristics did not diff er between individuals with MDR tuberculosis from TBESC states and those in the rest of the USA during the study period, with the exception of ethnic origin. TBESC (41%) were deemed to have reactivation of tuberculosis, of whom 14 (15%) had a known previous episode of tuberculosis outside the USA. Five individuals (5%) had documented treatment of a previous episode within the USA, and so were deemed to have relapsed. For nine cases (10%), insuffi cient evidence was available to defi nitively classify reason for presentation. Of the 92 individuals who underwent in-depth interview and health-record abstraction, 26 (28%) had the same genotype as another case of MDR tuberculosis in the same state during the surveillance period. Extended typing data were available for comparison for all but two pairs of cases. The lack of extended genotyping results in these cases did not aff ect classifi cation of the likelihood of transmission. 14 M tuberculosis clusters were associated with US transmission (table 3). 13 (93%) M tuberculosis isolates were of Euro-American phylogenetic lineage. Eight clusters (57%) had an identifi able source case, seven (50%) were characterised by abuse of illicit drugs or alcohol, two (14%) included confi rmed transmission to a child, 27 and one included transmission across state lines (table 3) . 8 Overall, people with MDR tuberculosis attributed to transmission in the USA were more likely to be male (p<0·0001), have been born in the USA (p<0·0001), be of Hispanic ethnic origin (p<0·0001), abuse illicit drugs or alcohol (p<0·0001), and to have an M tuberculosis isolate of Euro-American lineage (p<0·0001) than were those who had disease not attributed to transmission in the USA (table 4) .
75 (82%) of the 92 individuals who had an in-depth interview and health-record abstraction were born outside the USA. The 12 individuals whose disease was linked with transmission in the USA but of unknown source were all born outside the USA, and four were identifi ed as the source case for others. Nine were diagnosed at least 12 months after US entry, and none had a US medical examination on arrival in the country. 13 For the eight individuals for whom a known source case was identifi ed, only three source cases were born in the USA. There were two US-born, paediatric MDR tuberculosis cases included in the study: both children were infected by people born outside the USA who had been diagnosed with MDR tuberculosis within 12 Table 4 : Characteristics of patients with multidrug-resistant tuberculosis who consented to an in-depth interview diagnosis occurred within 3 months of immigration, their M tuberculosis isolates were non-clustering genotypes, and no epidemiological links were identifi ed. During our study period, we identifi ed 1166 people by contact investigation who were exposed to MDR tuberculosis, of whom 353 (30%) were diagnosed with latent tuberculosis infection. Although which individuals will go on to develop active MDR tuberculosis is unclear, with the assumption that 10% will develop active disease, 28 35 new cases of MDR tuberculosis could emerge in the USA from our cohort in the absence of effi cacious preventive treatment.
Discussion
In this multicentre, multiyear, population-based study, transmission occurred in roughly a fi fth of individuals with MDR tuberculosis. Although most people diagnosed with MDR tuberculosis were born outside of the USA, some were linked to transmission in the USA, including four individuals who were the source of transmission for other cases. A substantial proportion of MDR tuberculosis cases represented reactivation of tuberculosis or disease acquired outside the USA (20 imported active disease, 14 known previous episode outside the USA, fi ve documented treatment of previous episode within the USA; 42%), including 17 that were diagnosed within 3 months of entry into the USA.
The proportion of MDR tuberculosis cases attributed to transmission within the USA in our study (22%) was similar to that in another report of genotyped cases reported in the USA (23%), 22 but higher than values reported for the state of California (14% 14 and 8% 18 ). However, in these previous studies, 14, 18, 22 detailed information about interpersonal connections between cases was not available, and thus genotyping results alone were used as a proxy to determine tuberculosis transmission. In a study following the major outbreak of MDR tuberculosis and resurgence of tuberculosis in New York City (NY, USA), 29 about 13% of genotyped MDR tuberculosis cases were epidemiologically linked by medical-record review and interview of patients, most of whom were exposed to MDR tuberculosis long before the study. 17 Notably, in our study, half the identifi ed source cases were born outside the USA. This fi nding contrasts with those of other studies, which have suggested that transmission of M tuberculosis within a country generally occurs between individuals born there, 17, 18, 22, 23 and rarely occurs between these people and those born elsewhere. 30 Therefore, our fi ndings could have important implications for algorithms that assign the likelihood of tuberculosis transmission in the USA in the absence of routinely identifi ed epidemiological linkages and because important transmission events might be missed in people born elsewhere. 31 The large proportion of cases of reactivated disease acquired outside the USA might have been prevented had appropriate diagnostic screening and treatment been implemented at or before immigration (reducing the potential for transmission in the USA). Our results were similar to those of a cross-sectional study of all patients born outside the USA with an M tuberculosis isolate genotyped in the USA between 2005 and 2009: 23 50% of cases were attributable to reactivation of disease acquired elsewhere. Importantly, the primary purpose of the present US immigration screening programme is to identify active disease, and not latent tuberculosis infection. 32 There is no policy to test for latent tuberculosis infection in adults born outside the USA before or during the US entry process. 32 Moreover, for individuals who already live in the USA but were born elsewhere, present guidelines 33 recommend testing for latent tuberculosis infection only for those who have been in the USA for less than 5 years.
More importantly, prevention of transmission and progression to active disease is more challenging after exposure to MDR M tuberculosis than after exposure to drug-susceptible M tuberculosis. The principal strategy to interrupt tuberculosis transmission and reduce the likelihood of remote reactivation of disease is to use treatment for latent infection. Several treatment regimens are available for people who have latent
Panel: Research in context
Systematic review
We searched PubMed with the term: "(tuberculosis OR TB) AND (multidrug resistance OR MDR) AND (transmission)" for reports published in any language between Jan 1, 1965, and April 31, 2013. We identifi ed 630 reports, of which 134 were of peer-reviewed studies and contained original data for the epidemiology of drug-resistant tuberculosis, such as information about patients and tuberculosis genotype data. In 96 studies, information about interpersonal connections or transmission venues (as needed to accurately identify transmission events) was not obtained. 35 studies were done in outbreak conditions or were narrowly focused on specifi c groups, such as health-care workers, household contacts, people living with HIV infection, prisoners, or miners. Of the remaining three population-based studies that investigated transmission of multidrug-resistant (MDR) tuberculosis, only one was based in the USA: it was done in one state more than a decade ago.
Interpretation
As far as we are aware, ours is the largest multicentre, population-based study to include detailed information about the potential contributing factors of transmission of MDR tuberculosis. We showed that as many as one in every fi ve individuals diagnosed with MDR tuberculosis in the USA could be linked to transmission. Evidence-based standardised regimens are urgently needed for people exposed to MDR tuberculosis to prevent progression to active disease. tuberculosis and are exposed to drug-susceptible M tuberculosis, including a once weekly, 12-dose regimen. 34 However, because all isolates of MDR M tuberculosis have resistance to isoniazid and rifampicin, most evidence-based regimens are not appropriate for individuals exposed to MDR tuberculosis. The American Thoracic Society and CDC recommend that immuno competent people exposed to MDR tuberculosis be followed up for 24 months, irrespective of treatment. 33 When treatment is given, a two-drug regimen taken for 6-12 months is recommended if bacteria from the index case are known to be susceptible to pyrazinamide and ethambutol, or pyrazinamide and a fl uoroquinolone. 33 Unfortunately both pyrazinamide regimens have high toxicity; 35, 36 thus, careful follow-up without any treatment is a justifi able option for immunocompetent individuals. Therefore, the decision to treat latent tuberculosis infection as a result of exposure to MDR disease-and how to go about it-remains highly controversial.
As yet, no randomised controlled trials of the effi cacy of recommended treatment combinations for latent MDR tuberculosis infection have been reported. 37 Several approvals for new antituberculosis drugs are imminent, including some with early bactericidal activity, 38,39 but these drugs might not be available for routine clinical care for several years. Because these drugs are being developed primarily to shorten treatment and improve clinical outcomes, whether they will be eff ective in prophylaxis or whether they should be used at all for latent infection to protect against potential acquired drug resistance is unknown. 40, 41 During our study, contact investigation identifi ed 1166 individuals who were exposed to MDR tuberculosis, including 353 (30%) diagnosed with latent tuberculosis infection. Although which individuals will go on to develop active disease is unclear, 35 new cases will potentially emerge in the future in the USA from this cohort without effi cacious preventive treatment.
Our study was one of the largest population-based studies of MDR tuberculosis transmission (panel), and we included all genotyped cases reported in eight states during the surveillance period, but only about 60% of eligible cases were available for in-depth interview. Genotypic and epidemiological linkages based on both interview and public health records provided a strong assessment of transmission between enrolled individuals, but because not all isolates received all three genotyping methods (ie, spoligotyping, 24-locus MIRU-VNTR and IS6110-RFLP), some clusters could possibly be divided into small subsets. Therefore, we might have underestimated transmission. Moreover, not all individuals with MDR tuberculosis, including those in adjacent states, were interviewed, so we might have under estimated the proportion of cases with epidemiological linkages and therefore trans mission between states. Additionally, because MDR tuber culosis was a rare event, our sample size was small and cell size could aff ect some statistical inferences.
In conclusion, although roughly four-fi fths of individuals with MDR tuberculosis included in our study were born outside the USA, a fi fth could be linked to transmission after immigration. These fi ndings, in addition to the substantial proportion of cases that were reactivation of MDR disease or disease acquired outside the USA, further emphasise the immediate need for evidence-based, standardised regimens to prevent transmission of MDR tuberculosis and progression of active disease.
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